Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elsunersen in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy
NCT07019922Phase 3Recruiting
- Sponsor
- Praxis Precision Medicines
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 4
01
Overview
A Phase 3 trial of elsunersen in SCN2A developmental and epileptic encephalopathy (SCN2A-DEE), sponsored by Praxis Precision Medicines. Started Aug 2025; status: recruiting.
02
Drugs
elsunersen
03
Conditions
SCN2A developmental and epileptic encephalopathy (SCN2A-DEE)
Beyond the preview
Go deeper on NCT07019922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07019922.